METHODS FOR IMPROVING BLOOD GLUCOSE CONTROL

• US 20120295985A1
• Filed: 11/18/2011
• Published: 11/22/2012
• Est. Priority Date: 11/19/2010
• Status: Abandoned Application

• Current Assignee: Edison Pharmaceuticals, Inc.
• Original Assignee: Edison Pharmaceuticals, Inc.
• Inventors: Miller, Guy M., Shrader, William D., Thoolen, Martin J.
• Application Number:
  US13/300,449
• Publication Number:
  US 20120295985A1
• Time in Patent Office: Days
• US Class Current: 514/690
• CPC Class Codes: A61K 31/122 having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• CPC Class Codes: A61K 31/20 having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention is concerned with a method for improving blood glucose control or for preventing or treating a condition requiring increasing insulin sensitivity or reducing insulin resistance in a subject in need of such control which comprises administering to the subject a composition comprising a therapeutically effective amount of one or more quinones of Formula I.

Claims

1. A composition comprising one or more compounds of Formula I in an amount effective for improving blood glucose control in a subject with abnormal glucose tolerance and metabolism in need of such treatment, where the compounds of Formula I have the following structure:

2. position according to claim 1, comprising one or more compounds of Formula I selected from alpha-tocotrienol quinone, beta-tocotrienol quinone, gamma-tocotrienol quinone, and delta-tocotrienol quinone, or any stereoisomer, or mixture of stereoisomers thereof.

3. The composition according to claim 1, comprising alpha-tocotrienol quinone or any stereoisomer, or mixture of stereoisomers thereof.

4. A composition comprising one or more compounds of Formula I according to claim 1, in an amount effective for preventing, reducing, ameliorating or treating diabetes, or to stabilize the level of blood sugar, stop the increase in level of blood sugar, reverse the increase in the level of blood sugar, or reduce the level of blood sugar in a subject with abnormal glucose tolerance and metabolism in need of such treatment.

5. position according to claim 4, comprising one or more compounds of Formula I selected from alpha-tocotrienol quinone, beta-tocotrienol quinone, gamma-tocotrienol quinone, and delta-tocotrienol quinone or any stereoisomer, or mixture of stereoisomers thereof.

6. The composition according to claim 5, comprising alpha-tocotrienol quinone, or any stereoisomer, or mixture of stereoisomers thereof.

7. A composition comprising one or more compounds of Formula I according to claim 1, in an amount effective for preventing or treating a condition requiring increasing insulin sensitivity or reducing insulin resistance in a subject with abnormal glucose tolerance and metabolism in need of such treatment.

8. The composition according to claim 7, comprising one or more compounds of Formula I selected from alpha-tocotrienol quinone, beta-tocotrienol quinone, gamma-tocotrienol quinone, and delta-tocotrienol quinone or any stereoisomer, or mixture of stereoisomers thereof.

9. The composition according to claim 8, comprising alpha-tocotrienol quinone, or any stereoisomer, or mixture of stereoisomers thereof.

10. A composition comprising one or more compounds of Formula I according to claim 1, in an amount effective for preventing, reducing, ameliorating or treating vascular disease complications, including retinopathy and nephropathy, in a subject with abnormal glucose tolerance and metabolism in need of such treatment.

11. The composition according to claim 10, comprising one or more compounds of Formula I selected from alpha-tocotrienol quinone, beta-tocotrienol quinone, gamma-tocotrienol quinone, and delta-tocotrienol quinone or any stereoisomer, or mixture of stereoisomers thereof.

12. The composition according to claim 11, comprising alpha-tocotrienol quinone, or any stereoisomer, or mixture of stereoisomers thereof.

13. A composition comprising one or more compounds of Formula I according to claim 1, in an amount effective for preventing, reducing, ameliorating or treating inflammation in a subject with abnormal glucose tolerance and metabolism in need of such treatment.

14. The composition according to claim 13, comprising one or more compounds of Formula I selected from alpha-tocotrienol quinone, beta-tocotrienol quinone, gamma-tocotrienol quinone, and delta-tocotrienol quinone or any stereoisomer, or mixture of stereoisomers thereof.

15. The composition according to claim 14, comprising alpha-tocotrienol quinone, or any stereoisomer, or mixture of stereoisomers thereof.

16. A formulation comprising one or more compounds of Formula I according to claim 1, and, optionally, a pharmaceutically acceptable carrier, diluent or excipient, in an amount effective for improving blood glucose control in a subject with abnormal glucose tolerance and metabolism in need of such treatment.

17. A formulation comprising one or more compounds of Formula I according to claim 1, and, optionally, a pharmaceutically acceptable carrier, diluent or excipient, in an amount effective for preventing, reducing, ameliorating or treating diabetes, or to stabilize the level of blood sugar, stop the increase in level of blood sugar, reverse the increase in the level of blood sugar, or reduce the level of blood sugar in a subject with abnormal glucose tolerance and metabolism in need of such treatment.

18. A formulation comprising one or more compounds of Formula I according to claim 1, and, optionally, a pharmaceutically acceptable carrier, diluent or excipient, in an amount effective for preventing or treating a condition requiring increasing insulin sensitivity or reducing insulin resistance in a subject with abnormal glucose tolerance and metabolism in need of such treatment.

19. A formulation comprising one or more compounds of Formula I according to claim 1, and, optionally, a pharmaceutically acceptable carrier, diluent or excipient, in an amount effective for preventing, reducing, ameliorating or treating vascular disease complications, including retinopathy and nephropathy, in a subject with abnormal glucose tolerance and metabolism in need of such treatment.

20. A formulation comprising one or more compounds of Formula I according to claim 1, and, optionally, a pharmaceutically acceptable carrier, diluent or excipient, in an amount effective for preventing or treating inflammation in a subject with abnormal glucose tolerance and metabolism in need of such treatment.

21. A method for improving blood glucose control in a subject with abnormal glucose tolerance and metabolism in need of such treatment which comprises administering an effective amount of one or more compounds of Formula I of claim 1 and, optionally, a pharmaceutically acceptable carrier, diluent or excipient.

22. The method according to claim 21, comprising administering an effective amount of one or more compounds of Formula I selected from alpha-tocotrienol quinone, beta-tocotrienol quinone, gamma-tocotrienol quinone, and delta-tocotrienol quinone, or any stereoisomer, or mixture of stereoisomers thereof.

23. The method according to claim 22, comprising administering an effective amount of alpha-tocotrienol quinone, or any stereoisomer, or mixture of stereoisomers thereof.

24. A method for preventing, reducing, ameliorating or treating diabetes, or to stabilize the level of blood sugar, stop the increase in level of blood sugar, reverse the increase in the level of blood sugar, or reduce the level of blood sugar in a subject with abnormal glucose tolerance and metabolism in need of such treatment, which comprises administering an effective amount of one or more compounds of Formula I of claim 1 and, optionally, a pharmaceutically acceptable carrier, diluent or excipient.

25. The method according to claim 24, comprising administering an effective amount of one or more compounds of Formula I selected from alpha-tocotrienol quinone, beta-tocotrienol quinone, gamma-tocotrienol quinone, and delta-tocotrienol quinone, or any stereoisomer, or mixture of stereoisomers thereof.

26. The method according to claim 25, comprising administering an effective amount of alpha-tocotrienol quinone, or any stereoisomer, or mixture of stereoisomers thereof.

27. A method for preventing or treating a condition requiring increasing insulin sensitivity or reducing insulin resistance in a subject with abnormal glucose tolerance and metabolism in need of such treatment which comprises administering an effective amount of one or more compounds of Formula I and, optionally, a pharmaceutically acceptable carrier, diluent or excipient according to claim 1.

28. The method according to claim 27, comprising administering an effective amount of one or more compounds of Formula I selected from alpha-tocotrienol quinone, beta-tocotrienol quinone, gamma-tocotrienol quinone, and delta-tocotrienol quinone, or any stereoisomer, or mixture of stereoisomers thereof.

29. The method according to claim 28, comprising administering an effective amount of alpha-tocotrienol quinone, or any stereoisomer, or mixture of stereoisomers thereof.

30. A method for preventing, reducing, ameliorating or treating vascular disease complications of diabetes, including retinopathy and nephropathy, in a subject with abnormal glucose tolerance and metabolism in need of such treatment, which comprises administering an effective amount of one or more compounds of Formula I of claim 1, and, optionally, a pharmaceutically acceptable carrier, diluent or excipient.

31. The method according to claim 30, comprising administering an effective amount of one or more compounds of Formula I selected from alpha-tocotrienol quinone, beta-tocotrienol quinone, gamma-tocotrienol quinone, and delta-tocotrienol quinone, or any stereoisomer, or mixture of stereoisomers thereof.

32. The method according to claim 31, comprising administering an effective amount of alpha-tocotrienol quinone, or any stereoisomer, or mixture of stereoisomers thereof.

33. A method for preventing, reducing, ameliorating or treating inflammation in a subject with abnormal glucose tolerance and metabolism in need of such treatment, which comprises administering an effective amount of one or more compounds of Formula I of claim 1, and, optionally, a pharmaceutically acceptable carrier, diluent or excipient.

34. The method according to claim 33, comprising administering an effective amount of one or more compounds of Formula I selected from alpha-tocotrienol quinone, beta-tocotrienol quinone, gamma-tocotrienol quinone, and delta-tocotrienol quinone, or any stereoisomer, or mixture of stereoisomers thereof.

35. The method according to claim 34, comprising administering an effective amount of alpha-tocotrienol quinone, or any stereoisomer, or mixture of stereoisomers thereof.

36. The method of claim 21, wherein the formulation is administered orally or enterally.

37. The method of claim 24, wherein the formulation is administered orally or enterally.

38. The method of claim 27, wherein the formulation is administered orally or enterally.

39. The method of claim 30, wherein the formulation is administered orally or enterally.

40. The method of claim 33, wherein the formulation is administered orally or enterally.